Complete Guide to Dupilumab Pharmacokinetics
Overview
Dupilumab is a mAb used in the Immunology therapeutic area. It is indicated for Atopic Dermatitis. Population PK simulator for dupilumab (Dupixent) in atopic dermatitis. Explore weight-based dosing and exposure targets.
Mechanism of Action
Dupilumab exerts its pharmacological effect by targeting IL-4Rα. As a mAb, it modulates this target to achieve therapeutic efficacy in Atopic Dermatitis. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published PopPK models for Dupilumab:
| Parameter | Value |
|---|---|
| Q | 0.263 L/day |
| Ka | 0.263 1/day |
| Ke | 0.0418 1/day |
| Km | 2.08 mg/L |
| V2 | 2.76 L |
| Vc | 2.76 L |
| Vp | 1.61 L |
| Fsc | 0.609 |
| K23 | 0.0952 1/day |
| K32 | 0.163 1/day |
| Vmax | 1.39 mg/L/day |
| dose | 300 mg SC q2w (atopic dermatitis) |
| IIV CL | 19.6% CV (Ke) |
| t half | ~16.6 days (linear component) |
| CL linear | 0.115 L/day |
| protein binding | minimal (target-mediated) |
| bioavailability SC | 0.609 |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Dupilumab is administered via the SC route. Subcutaneous administration provides sustained absorption from the injection site. Bioavailability and absorption rate may vary by injection site and volume.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Immunology therapeutic area, for the treatment of Atopic Dermatitis, understanding the pharmacokinetics of Dupilumab is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Dupilumab pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Dupilumab PK Simulator
Explore Dupilumab pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Dupilumab?
The elimination half-life of Dupilumab depends on patient-specific factors. Based on published models, the typical half-life is approximately ~16.6 days (linear component).
How is Dupilumab administered?
Dupilumab is administered via the SC route. It is indicated for Atopic Dermatitis. As a mAb, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Dupilumab?
Key pharmacokinetic parameters for Dupilumab include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Dupilumab dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Dupilumab PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.